Go Pro
→ A letter from Shannon Stansberry (From Porter & Company) (Ad)tc pixel
NASDAQ:INVA

Innoviva Q2 2026 Earnings Report

Innoviva logo
$22.20 -0.23 (-1.03%)
Closing price 04:00 PM Eastern
Extended Trading
$22.20 0.00 (0.00%)
As of 06:38 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.
ProfileEarnings HistoryForecast

Innoviva EPS Results

Actual EPS
N/A
Consensus EPS
$0.44
Beat/Miss
N/A
One Year Ago EPS
N/A

Innoviva Revenue Results

Actual Revenue
N/A
Expected Revenue
$110.99 million
Beat/Miss
N/A
YoY Revenue Growth
N/A

Innoviva Announcement Details

Quarter
Q2 2026
Date
8/5/2026
Time
Before Market Opens
Conference Call Date
Thursday, July 30, 2026
Conference Call Time
4:00PM ET

Conference Call Resources

Innoviva Earnings Headlines

Major Theravance Biopharma Investor Makes Notable Stock Move
July 8 at 10:10 PM  |  tipranks.comhttps://www.tipranks.com/news/insider-trading/major-theravance-biopharma-investor-makes-notable-stock-move-insider-trading-news?utm_source=marketbeat.com&utm_medium=referral
Innoviva, Inc. (NASDAQ:INVA) Given Average Recommendation of "Moderate Buy" by Brokerages
July 2, 2026  |  americanbankingnews.comhttps://www.americanbankingnews.com/?p=30874516
Do NOT Buy SpaceX – Do This Instead
SpaceX just went public - and Whitney Tilson, Harvard MBA and 30-year Wall Street veteran, says buying in could be a costly mistake. He calls it among the most overhyped, overvalued large-cap offerings ever pushed onto everyday investors. Tilson believes a rare economic event is approaching - one with serious consequences for your portfolio this summer. He has prepared a free analysis outlining what he sees and the specific steps he recommends taking now.tc pixel
July 9 at 1:00 AM  |  Stansberry Research (Ad)
Major Insider Move Rocks Theravance Biopharma Shares
July 1, 2026  |  tipranks.comhttps://www.tipranks.com/news/insider-trading/major-insider-move-rocks-theravance-biopharma-shares-insider-trading-news?utm_source=marketbeat.com&utm_medium=referral
Is Innoviva (INVA) One of the Best Cheap Small Cap Stocks to Buy Now?
July 1, 2026  |  insidermonkey.comhttps://www.insidermonkey.com/blog/is-innoviva-inva-one-of-the-best-cheap-small-cap-stocks-to-buy-now-1792985/
5 Cheap Small Cap Stocks to Buy Now
June 30, 2026  |  insidermonkey.comhttps://www.insidermonkey.com/blog/5-cheap-small-cap-stocks-to-buy-now-1791285/
See More Innoviva Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Innoviva? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Innoviva and other key companies, straight to your email.

About Innoviva

Innoviva (NASDAQ:INVA), incorporated in Delaware and headquartered in San Francisco, California, is a royalty-focused life sciences company. It acquires, manages and monetizes royalty and license interests in biopharmaceutical products, with a primary emphasis on inhaled respiratory therapies. Innoviva’s portfolio is anchored by royalties on therapies originally developed by its former affiliate, now marketed by GlaxoSmithKline, including several long-acting inhaled products approved for chronic obstructive pulmonary disease (COPD) and asthma.

The company was established through a spin‐out transaction in 2014, separating the royalty assets from a research‐based biopharmaceutical enterprise to create a specialized investment vehicle. Since its formation, Innoviva has supplemented its core royalty stream with additional licensing and collaboration agreements, and has pursued disciplined capital‐allocation activities to maximize dividend payments to shareholders. The firm’s contractual arrangements typically provide for tiered royalties on net sales as well as potential milestone receipts upon regulatory approvals and commercial launches.

Innoviva’s royalty revenues are generated globally through collaboration partners that market, distribute and promote the underlying therapeutics both in the United States and in international territories. The company maintains a lean corporate structure, relying on third‐party manufacturing, regulatory and commercialization expertise. Innoviva is governed by an experienced board of directors and led by management professionals with backgrounds in pharmaceutical licensing, royalty financing and capital markets.

View Innoviva Profile
Earnings Tools